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Cachexia, a paraneoplastic syndrome markedly associated with worsened prognosis in cancer patients,
provokes profound wasting of both lean and adipose mass in an association with a state of metabolic
‘‘chaos’’. The white adipose tissue responds to cachexia with marked local inﬂammation and may be thus
a relevant contributor to systemic inﬂammation. To address this hypothesis we examined the correlation
between tissue expression of adipokines and plasma concentration in cachectic and stable weight
patients with or without cancer. Adiponectin and liver-derived CRP concentration were signiﬁcantly
higher in the cachectic groups when compared with stable weight patients (P < 0.01). The concentration
of plasma IL-6 was higher (11.4-fold) in the cancer cachectic group when compared with weight-stable
controls, and presented a signiﬁcant correlation with the presence of cancer (P < 0.001). A marked
increase (5-fold) in IL-6 as a result of the interaction between the presence of cachexia and the presence
of tumour was observed in the subcutaneous tissue of the patients, yet not in the visceral depot. Plasma
adiponectin levels were higher in cachectic cancer patients, compared with stable weight cancer patients
individually matched by age, sex, and BMI, and the subcutaneous depot was found to be the main con-
tributing tissue, rather than the visceral pad. Based on the results we concluded that the subcutaneous
adipose tissue is associated with plasma changes that may function as markers of cachexia.
 2012 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Cachexia, a wasting syndrome is associated with 22–40% of can-
cer deaths [1,2]. Progressive cachexia represents an independent
prognostic factor concerning the response to antineoplastic ther-
apy and survival [3], and has been recently deﬁned as ‘‘a multifac-
tor syndrome characterized by ongoing loss of skeletal muscle
mass (with or without loss of fat mass) that cannot be fully re-
versed by conventional nutritional support and leads to progres-
sive functional impairment’’ [4]. Although muscle wasting has
been the main focus of cachexia-related research [5,6], studies
show that fat loss occurs more rapidly and more precociously than
the reduction of lean mass in cancer cachexia [7,8], and may ex-
tend up to 80% within a very short interval, especially in the imme-
diate period preceding death [9].
The underlying molecular basis of cachexia is still poorly under-
stood, yet the perspective of the syndrome as a chronic inﬂamma-
tory state, in which the host’s reaction to the presence of the2.
r).
sevier OA license.tumour seems to be the main causal agent, is gaining crescent
acceptance [10–12]. Inﬂammation may be a result of the produc-
tion of mediators deriving both from the tumour and from the
host’s tissues, among which inﬂammatory cytokines appear as ma-
jor contributors [6].
We have shown [13–15] that the white adipose tissue (WAT)
actively expresses and secretes a plethora of pro-inﬂammatory fac-
tors in a rodent model of cancer cachexia and may thus be consid-
ered an important subscriber to the characteristic systemic
inﬂammation. Furthermore, we hereby propose that factors deriv-
ing from this tissue may be adopted as markers for the diagnosis
and grading of the syndrome, based on the aforementioned animal
studies and on the results we now present with cancer patients.
WAT has been shown to largely subsidise systemic inﬂamma-
tion in a variety of diseases, as it has, over the last decades, been
recognised to be a major endocrine organ, capable of actively syn-
thesising and secreting a plethora of humoral factors, the adipo-
kines, among which leptin, adiponectin, TNF-a, IL-6, IL-10,
plasminogen activator inhibitor-1 and visfatin; all of which act lo-
cally in an autocrine/paracrine manner and/or as endocrine signals
in the regulation of appetite, energy expenditure and a range of
physiological processes including insulin sensitivity and the inﬂam-
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the adipose tissue and the tumour, such as interleukin 6 (IL-6), tu-
mour necrosis factor a (TNF-a) or zinc-a2 glycoprotein (ZAG) con-
tributes to the disrupted lipidmetabolism and increased lipolysis in
cancer cachexia [5,17]. Therefore, the white adipose tissue is both a
victim and a sponsor of cachexia-related systemic inﬂammation.
In this study we present results with gastrointestinal cancer pa-
tients that may support the adoption of WAT-derived factors as
markers of cachexia. The recently proposed grading of cachexia
[2], envisaging three stages, namely; pre-cachexia, cachexia, and
refractory cachexia, signals the necessity of establishment of tools
allowing for unequivocal diagnosis aiming at precise intervention,
according to the patient’s actual disease stage and prevention of its
aggravation.
2. Patients and methods
2.1. Patients
All patients were recruited between November 2008 and July
2011 at the ambulatory surgery division from the University Hos-
pital of the University of São Paulo (n = 235). The inclusion criteria
were; 1 – no prior anticancer treatment, 2 – not having clinical evi-
dence of gastrointestinal obstruction, 3 – ﬁtting into the logistical
scheme for scientiﬁc studies before operation or preoperative
treatment and 4 – willingness to participate (n = 61). The exclusion
criteria were liver failure, renal failure, AIDS, inﬂammatory dis-
eases of the bowel and autoimmune disorders. The study was ap-
proved by the Regional Ethics Committee (CEP-HU/USP 752/07,
CAAE 0031.0.198.019-07). The investigation was explained in de-
tail to each patient and a written informed consent was obtained.
The patients were divided into four groups based on diagnosis after
surgery. The cachectic groups were subdivided into two groups:
cancer cachexia (n = 31), and control (non-cancer) cachexia
(n = 8). Cancer cachexia was deﬁned as prediagnosed gastrointesti-
nal cancer with no evidence of gastrointestinal obstruction or an-
orexia with nausea and/or stomach pain, in combination with
unintentional weight loss of >5% of the habitual weight during
the last 3 months or >10% weight loss during the last 6 months.
The same criteria were adopted to classify control cachexia,
excluding cancer diagnosis. The weight-stable groups (no impor-
tant weight change during last year and BMI <25) were divided
into weight-stable cancer (n = 12) and weight-stable control
(non-cancer) patients (control, n = 10). In the cancer groups, the tu-
mour primary location was: colon (n = 14), stomach (n = 13), pan-
creas (n = 3), rectum (n = 2), and others (n = 11). The cachectic
control group was composed by patients with: cirrhosis (n = 3),
chronic pancreatitis (n = 3), and gastric or duodenal ulcers (n = 2).
The weight-stable control group included patients undergoing sur-
gery for incisional (n = 7), inguinal (n = 2) and umbilical (n = 1) her-
nia. The study was designed as ‘‘intention to compare’’; therefore,
all subjects were kept in the analyses despite a few missing values
of the measurements. The remaining 174 patients were excluded
because (a) although pre-diagnosed with gastrointestinal cancer
they did not have malignancy according to ﬁnal histological evalu-
ations (n = 41) or (b) could not provide adequate amounts of adi-
pose tissue, at least 0.9 g or (c) could not provide, for the same
patient, samples from subcutaneous and omental adipose tissue
depots and samples related with inﬂammatory and biochemical
parameters, for a complete investigation. Table 1 presents the gen-
eral characteristics of patients in each group.
2.2. Clinical parameters assessment
Height and weight were determined and approximately 10 mL
of blood were collected after an overnight fasting, within the ve-nous access procedure for anaesthesia during the surgery, allowing
the measurement of plasma lipids, glucose, serum urea, and hemo-
globin. Plasma and serum samples were immediately frozen at
80 C until further analysis. Tumour staging was determined
postoperatively according to the guidelines of the UICC TNM
[18]. Cachexia staging, anorexia and inﬂammation were assessed
by the Cachexia score [19].
2.3. Adipose tissue biopsies
Approximately 1 g of subcutaneous and omental white adipose
tissue (by approximate anatomical site), were collected at 5 min
intervals, similarly to described by [17]. Tissue samples were rap-
idly rinsed in saline, frozen in liquid nitrogen, and kept at 80 C
for further analyses. This procedure presented a minimal degree
of risk, and did not interfere with surgery routine.
2.4. Plasma measurements
ELISA kits were employed for the measurements of TNF-a and
IL6 (CytoSet™, Invitrogen); CRP (cat.# HCVD2-67BK-01), Adipo-
nectin (cat.# HADK1-61K-A), Leptin (cat.#HENDO-65K-01), IL10
(cat.# MPXHCYTO-60K-02), (Genese Produtos Diagnósticos Ltda.,
Brasil) and Multiplex kits, for Luminex platform (R&D Systems,
USA). Adipokine and cytokines concentration was determined in
triplicate, and the mean was used for analysis. The inter-assay
CV over all ranges was lower than 12%.
2.5. Gene expression analysis
Total RNA of the samples was isolated with TriPure Isolation Re-
agent (Roche) following the recommendations of manufacturer
and total RNA concentrations quantiﬁed by spectrophotometry
(Nanodrop ND-1000). Complementary DNA synthesis was carried
out with 13 ll assay mix containing 3 lg total RNA, 10U RNAse
inhibitor, 2 ll random primers, 2 ll dNTP (10 nmol), 2 ll dithio-
threitol, 10U M-MLV reverse transcriptase and 4 ll of 10 reaction
buffer (100 mM TRIS–HCl, 500 mM KCl; 150 nM MgCl2 in nuclease
free water) (Invitrogen). The mRNA expression of the following
genes was determined: IL-6 (NM_000600.3, Forward 50TAC CCC
CAG GAG AAG ATT CC30, Reverse 50AGG TTG TTT TCT GCC AGT
GC30), Adiponectin (NM_001177800.1, Forward 50ATG ACC AGG
AAA CCA CGA CT30, Reverse 50CAC CGA TGT CTC CCT TAG GA30),
TNF-a (NM_000594.2, Forward 50 CTC TCT CCC CTG GAA AGG AC
30, Reverse 50ATC ACT CCA AAG TGC AGCA G30), IL-10
(NM_000572.2, Forward 50CCA AGC TGA GAA CCA AGA CC 30, Re-
verse 50AAG GCA TTC TTC ACC TGC TC 30), and leptin
(NM_000230.2, Forward 50GGA GGG CAA GGG CCA TGC TG03, Re-
verse 5CT GGC CAC AGC ACCA GCC TC03). Five lL of cDNA
(25 ng) were mixed with 2x SYBR Green PCR master mix (Applied
Biosystems) and primers (Invitrogen). Quantitative real-time PCR
was performed with an ABI 7300 Real Time Systems (Applied Bio-
systems). The mRNA levels were determined by comparative Ct
method for each sample. A DCt value was obtained by subtracting
18S values from those of the gene of interest. The average DCt va-
lue of the control group was then subtracted from the sample to
derive a DDCt value. The expression of each gene was evaluated
by 2-(DDCt).
2.6. Statistical analysis
The statistical analysis was performed with the commercially
available statistical package from SigmaStat (version 3.1, SigmaS-
tat, SYSTAT, Point Richmond, CA). Data were expressed as mean-
s ± SE and analysed by 2-way ANOVA of 2  2 design (cancer/
non-cancer-control vs. stable weight/cachexia). Data were parti-
Table 1
Characteristics of study groups.
Measure Weight-stable Cachexia ANOVA
Control Cancer Control Cancer
n 10 12 8 31
Gender (M/F) 6–4 8–4 5–3 19–12
Age (year) 63 ± 8 66 ± 13 65 ± 8 57 ± 15 –
Weight (kg) 57 ± 3 59 ± 8 52 ± 10 56 ± 17 –
Height (m) 1.5 ± 0.8 1.6 ± 1 1.6 ± 1 1.6 ± 1 –
BMI (kg/m2) 22 ± 1 23 ± 3 20 ± 4 21 ± 3 –
Weight loss (kg) 1.6 ± 1 1.5 ± 2 19 ± 11 13 ± 7 C., C.  T
Weight loss, relative (%) 3.0 ± 2 4.2 ± 2 26 ± 14 21 ± 8 C., C.  T
Tumour stage
IA 1% 10% 0% 0%
IB 0% 0% 1% 4%
IIA 0% 0% 0% 0%
IIB 1% 10% 3% 12%
IIIA 2% 20% 7% 28%
IIIB 2% 20% 2% 8%
IV 2% 40% 12% 48%
Adiponectin (lg/mL) 7.8 ± 2.7 11.1 ± 8.5 25.2 ± 17 19.1 ± 7.3 C.
Leptin (pM) 646 ± 158 309 ± 271 13.2 ± 12 221 ± 191 C.
Resistin (ng/mL) 15 0 + 26 11.3 ± 5.8 14.2 ± 10 15.7 ± 11
CRP (lg/mL) 3.1 ± 1.8 14.9 ± 13 18.4 ± 15 24.9 ± 14 C.
TNF (pg mL) 11.1 ± 4.5 13.8 ± 4.3 10.3 ± 5.9 72.5 ± 29 C.  T
IL-6 (pg/mL) 12.9 ± 3.6 30.3 ± 8.2 36.9 ± 20 160 ± 58 T, C.  T
IL-10 (pg/mL) 2.4 ± 0.7 4.9 ± 3.6 6.0 ± 8.6 24.3 ± 19
IL-6/IL-10 2.5 ± 0.8 6.0 ± 1.7 6.2 ± 2.5 24.8 ± 12 C.  T
Note: values are mean ± SD; n: number of patients; BMI: body mass index. Values that are signiﬁcantly different by two-way ANOVA are indicated by two-way ANOVA, C.
(stable weight vs. cachexia); T (tumor vs. non-tumor) and C  T (interaction between stable weight vs. cachexia and tumour vs. non-tumour).
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fects, A; and stable weight vs. cachexia group effects, B). The inter-
action effects consisted of A  B. When a signiﬁcant F value was
found by 2-way ANOVA, a Holm-Sidak post hoc test was performed
to demonstrate all pairwise multiple comparisons between the
means. Correlation analysis was conducted using Pearson correla-
tion or Spearman rank correlation tests. Stepwise method of multi-
ple regression analysis (with p < 0.05 as an entrance criterion and
p > 0.1 as a removal criterion) was applied in order to identify vari-
ables independently associated with cachexia (% weight loss and
BMI) and inﬂammatory (IL-6) parameters and to quantify the
strength of the association. All calculated p values were two-sided
and a p < 0.05 was considered signiﬁcant.Table 2
Association between cytokines and adipokines plasma levels and advancing cancer
disease stage in cachectic cancer patients.
Stages
I/II III IV ANOVA
n 6 9 12
Weight loss (%) 12.0 ± 1.7 19.7 ± 7.2 17.8 ± 5.3 0.077
Weight loss (A) 9.8 ± 1.8 14.0 ± 4.1 11.8 ± 4.1 0.160
BMI 22.9 ± 0.8 22.4 ± 3.7 21.3 ± 3.2 0.702
Adiponectin 9.9 ± 2.6 19.0 ± 7.9 13.5 ± 7.0 0.072
Leptin 276.2 ± 26.2 45.2 ± 27.0 222.7 ± 189.4 0.015
IL-6 37.4 ± 10.1 115.6 ± 56.9 415.7 ± 193.7 <0.001
CRP 23.1 ± 23.0 18.8 ± 20.5 26.8 ± 29.3 0.814
TNF 85.2 ± 56.1 57.1 ± 30.6 55.1 ± 51.7 0.823
IL-10 0.705 ± 0.3 32.5 ± 49 26.8 ± 42.8 0.382
BMI, body mass index; CRP, C-reactive protein; IL, interleukin; TNF, tumour necrosis
factor.3. Results
3.1. Clinical ﬁndings
Baseline characteristics of the patients are shown in Table 1.
The subjects in the four groups were of similar age and body mass
index (BMI). In this regard, we have not evaluated lean body mass
although groups were matched by BMI. The cancer cachexia group
showed a marked decrease in body weight. Subjects in the cachec-
tic groups (cachectic cancer and non-cancer patients) presented an
accentuated reduction of relative body weight compared with
weight-stable cancer (25.8 ± 14%) and control (20.6 ± 8.5%) within
the period between cancer diagnosis and surgery (p < 0.05; 2-
way ANOVA effect of cachexia). Plasma triglyceride levels were re-
duced in cachectic groups (p < 0.01; 2-way ANOVA effect of ca-
chexia). There was no difference with respect to other
biochemical parameters (i.e., plasma glucose, and serum urea, ser-
um haemoglobin values), however, the haemoglobin values found
in cachectic groups were lower than 12 g/dL, and plasma glucose
showed a tendency to be different (p = 0.076; 2-way ANOVA effectof cachexia). There was no difference between the weight-stable
cancer and cancer cachectic patients with respect to tumour stage.3.2. Inﬂammatory cytokine plasma levels are increased and IL-6
positively correlates with tumour stage
The concentration of IL-6 was shown to be affected by both can-
cer (p = 0.011; 2-way ANOVA effect of cancer) and the interaction
between the presence of cachexia and cancer (p = 0.011; 2-way
ANOVA effect of interaction factors) (Table 1). Furthermore, there
was an increase of IL-6 levels along the advancing disease stage
(Table 2), as well as a correlation with the incidence of distant
metastasis (p = 0.035, not shown), which was only related with
IL-6. The levels of TNF-awere signiﬁcantly higher in cachectic can-
cer patients (p = 0.046; 2-way ANOVA effect of interaction factors)
compared with controls (weight stable and cachexia) (Table 1).
There was no correlation between TNF-a plasma levels and cancer
M.L. Batista Jr. et al. / Cytokine 61 (2013) 532–539 535stage (data not shown). CRP levels were increased in those patients
with cachexia (p = 0.047 and p = 0.015; 2-way ANOVA effect of ca-
chexia, respectively) with no other detectable effect of cancer and/
or of interaction. IL-10 levels were not different among the groups.
IL-6 to IL-10 ratio (IL-6/IL-10) was affected by the interaction be-
tween the presence of cachexia and cancer (p = 0.005; 2-way ANO-
VA effect of interaction factors) (Table 1).
3.3. Adipokine plasma levels are disrupted in cancer cachexia
The mean concentration of adiponectin was much higher in
cachectic (cancer and non-cancer) patients (p = 0.010; 2-way ANO-
VA effect of cachexia) when compared with the weight stable
groups (cancer and non-cancer) (Table 1). Once body weight loss
is a hallmark of cachexia, we examined separately the percentage
of weight loss and BMI as different parameters. The strongest asso-
ciation was found between adiponectin levels and these two vari-
ables (percentage of weight loss, r = 0.67, p = 0.002 and BMI,
r = 0.56, p = 0.02) (Fig. 2).
3.4. IL-6 and adiponectin are more expressed in the subcutaneous vs.
visceral adipose tissue
IL-6 and adiponectin mRNA expression was examined in two
different adipose tissue pads (subcutaneous and visceral). IL-6
mRNA expression in the subcutaneous adipose tissue was affected
by the presence of the tumour (p = 0.001; 2-way ANOVA effect of
cancer), when compared with cachexia groups, with no effect of ca-
chexia and/or interaction (Fig. 1A). This increase was not evident in
samples from the visceral adipose tissue. The association between
plasma levels (r = 0.67, p = 0.002) and mRNA expression of IL-6Fig. 1. IL-6 mRNA expression in subcutaneous (SAT) and visceral (VAT) adipose tissue in c
(right side). Relationship between mRNA expression and plasma levels of IL-6 is shown in
otherwise linear regression was adopted. P = 0.001; 2-way ANOVA effect of cancer.(r = 0.56, p = 0.02) was observed just for the samples obtained
from the subcutaneous depot (Fig. 1B). Adiponectin mRNA expres-
sion in the subcutaneous adipose tissue was affected by the pres-
ence of cachexia (p = 0.005; 2-way ANOVA effect of cachexia) and
by the interaction between the presence of cachexia and tumour
(p = 0.036; 2-way ANOVA effect of interaction factors), when com-
pared with the weight stable controls (Fig. 2). Leptin and TNF-a
mRNA expression were altered in the subcutaneous adipose tissue
from cachectic (cancer and non-cancer) patients (p = 0.005 and
p = 0.009; 2-way ANOVA effect of cachexia, respectively) when
compared with the weight stable groups (cancer and non-cancer)
(Fig. 3A and B). IL-10 was affected by the interaction between can-
cer vs. cachexia (p = 0.046; 2-way ANOVA effect of interaction fac-
tors) compared with controls (weight stable and cachexia)
(Fig. 3C). No changes were detected in the visceral adipose tissue
regarding the same genes.
4. Discussion
A novel ﬁnding of this study was that the expression of some
molecules seems to be disrupted during cachexia while some other
may present increased expression with the interaction between
the presence of tumour and of cachexia development, notably IL-
6. Moreover, an association between adiponectin with body weight
loss, as well as a positive relationship between IL-6 and cancer T
stage suggests an important role of these molecules as potential
biomarkers of cancer cachexia. Due to the important role of adi-
pose tissue as a source of inﬂammatory mediators, we also exam-
ined the fat depot-speciﬁc expression of these molecules in
different WAT pads (VAT and SAT). We report depot-speciﬁc differ-
ences in adipose tissue mRNA expression of IL-6 and adiponectin,ancer cachexia, control cachexia, weight-stable with cancer and non-cancer patients
SAT (top left) and VAT (bottom left). ANOVA was employed in the right side graphs;
Fig. 2. Adiponectin mRNA expression in subcutaneous (SAT) and visceral (VAT) adipose tissue in cancer cachexia, control cachexia, weight-stable with cancer and non-cancer
patients (right side). Relationship between mRNA expression and plasma levels from adiponectin is shown from SAT (top central) and VAT (bottom central). ANOVA was
employed in the right side graphs; otherwise linear regression was adopted. Relationship between adiponectin plasma levels with BMI (top right) and body weight loss
(bottom right). P = 0.005; 2-way ANOVA effect of cachexia and P = 0.036; 2-way ANOVA effect of interaction factors.
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expression was unaffected.
It is clear nowadays that adipose tissue wasting precedes lean
mass degradation both in cancer patients and experimental models
of cachexia, and such symptom may be detected even before any
changes in food consumption are noticed [20,21]. In addition to
that, it is becoming increasingly clear that chronic systemic inﬂam-
mation is the hallmark of the syndrome, and that it may be
adopted for assessing not only the occurrence of cachexia, but in
addition, its depth [22,23]. The WAT contributes in a signiﬁcant
manner to systemic inﬂammation, as a potent source of inﬂamma-
tory factors [11]. Our results show an accentuated modiﬁcation in
the gene expression, as well as in plasma concentration of adipo-
kines and pro-inﬂammatory molecules in cachectic gastrointesti-
nal cancer patients, in relation to the non-cachectic counterparts.
These include adiponectin, leptin, TNF-a, IL-6, and IL-10. Moreover,
we have compared the contribution of the visceral and abdominal
subcutaneous pads, having found that the changes affecting the
latter may contribute for the development and progression of
cachexia.
With respect to TNF-a, cachectic cancer patients demonstrate a
6.5-fold increase in plasma concentration, as compared with the
stable weight controls, while subcutaneous adipose pad gene
expression is concomitantly increased by around 70-fold. The mag-
nitude of this alteration provides an early indication of the pres-
ence of marked local inﬂammation with systemic consequences
in the following steps of cachexia progression. Similarly, the reduc-
tion in SAT gene expression of leptin is more pronounced (around
6.5-fold) than that observed in plasma concentration (2.9-fold),
and adiponectin tissue expression (enhanced by 13.8-fold), follows
the same pattern, with plasma concentration varying 2.4-fold, so-
lely, as compared to control stable-weight patients (non-cancer).
Increased TNF-a concentration, along with augmented levels of
IL-6 and IL-10 have been frequently reported in cachectic cancerpatients, indicating that these cytokines seems to respond both
to the presence of the tumour and to the occurrence of cachexia:
marked alteration of cytokine circulating levels has recently been
reported in esophageal squamous cell carcinoma [24] as well as
in gastric adenocarcinoma [25,26], and in gastroesophageal cancer
patients [27,28]. It has been postulated that up-regulation of pro-
inﬂammatory cytokines is a common feature in the syndrome
[29], while reduction in food intake does not induce a detectable
increase in the circulating levels of these factors [30]. Therefore,
early alterations of higher magnitude of these well-established
markers may indeed contribute to precocious diagnosis.
Adipose tissue derived hormones, on the other hand, have been
claimed not to be correlated with inﬂammation in cachexia [31].
This assumption is based on the premise that they rather reﬂect
adipose tissue wasting, rather than actively contribute to the ca-
chexia-associated alterations. For instance, inconsistent results
show increased adiponectin levels and reduced BMI in cachectic
patients (positive correlation) [32,33], low levels in patients with
weight-loss in advanced lung cancer (negative correlation) [34],
or still, absence of correlation in cachexia patients [35]. For leptin,
this also stands true [36]. This inconsistence is partly due to the ab-
sence of individual controls matched by age, sex, BMI, and cancer
TNM stage, as well as presence of inﬂammatory disease related
to low grade inﬂammation of control groups [37].
Nevertheless, the studies examining human adipokines and ca-
chexia have focused on the plasma content of these factors, which
is the ﬁnal result of the different contributions of the many adipose
depots. We have previously shown in an animal model of cachexia,
that there is marked zonal heterogeneity of response to cachexia
among fat pads [38]. In addition, increased lipolysis in cancer ca-
chexia has been suggested as key factor in triggering the loss of
adipose tissue in these patients, notably in relation to subcutane-
ous pads [17,39]. The present results show that clear peculiarities
are associated with the anatomical localization of the depot, with
Fig. 3. Leptin (A), TNF-a (B) and IL-10 (C) mRNA expression in subcutaneous (SAT) and visceral (VAT) adipose tissue in cancer cachexia, control cachexia, weight-stable with
cancer and non-cancer patients (right side). ANOVA was employed in the right side graphs; otherwise linear regression was adopted. P = 0.005; 2-way ANOVA effect of
cachexia and P = 0.036; 2-way ANOVA effect of interaction factors.
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this in mind, it is possible to regard tissue expression differences
(13.8-fold for adiponectin and decreased 65.8% for leptin expres-
sion between control stable-weight patients and cancer cachexia
groups) as early markers of cachexia-related adipose wasting.
The reported changes in adiponectin from patients were found
to be markedly correlated with weight loss in the previous
6 months. Through BMI matching, we isolated the confounding ef-
fect of the inverse association between BMI and adiponectin. To the
best of our knowledge, no previous study has compared adiponec-
tin levels in BMI-matched cachectic and non-cachectic patients,
with or without gastrointestinal cancer. Therefore we may suggest,
corroborating [33], that the higher capacity for adiponectin pro-
duction in cachexia may contribute to the wasting process, as
adiponectin administration in experimental animal models has
been demonstrated to increase energy expenditure followed by
body weight lost [40].
Still regarding adiponectin, the higher levels herein reported
may have been inﬂuenced by differences in the characteristics of
our patients. The cancer cachectic group showed more advanced
tumour stage classiﬁcation and higher CRP values. The association
of adiponectin with tumour stage classiﬁcation in colorectal ade-
noma-bearing patients has been recently shown Nakajima [41],
however, we found no clear relationship between the degree of ca-
chexia and tumour staging. Indeed, it has been shown that patients
bearing very small tumour burdens may present profound cachex-
ia and worsened prognosis than those bearing large tumourmasses [42]. Furthermore, the cachectic cancer patients show in-
tense inﬂammatory activation (as demonstrated by high CRP),
accentuated body weight lost (about 20%), and lower haemoglobin
levels. Although these symptoms may simply reﬂect cachexia
severity, since cancer cachexia is a characteristic of advanced/
end-stage disease, a clear correlation between these variables with
adiponectin has never been reported.
The controversial results on leptin and cancer cachexia in the
literature [36] may also be related with the fact that the most of
the studies investigate the plasma levels of the hormone, rather
than adipose tissue expression. Tessitore et al. [43] described de-
creased leptin mRNA levels in the white adipose tissue of breast
and gynecological cancer patients, a result that is similar to that
we now report for the cachectic gastrointestinal cancer patients.
We may once again, imply that tissue modiﬁcations are more
appropriate for the precise detection of pathological changes. An-
other interesting ﬁnding still regarding the heterogeneous re-
sponse of white adipose tissue pads to cachexia, is the
subcutaneous tissue-speciﬁc increase of IL-6 expression. IL-6 is
considered to be an adipose tissue-derived lipolytic factor, and
thus plays an important role in promoting adipose wasting in can-
cer patients [39]. In addition, a marked positive relationship be-
tween subcutaneous pad IL-6 mRNA expression and plasma
levels of this cytokine was found, indicating that subcutaneous de-
pots may be an important source of IL-6 in cancer cachexia. There-
fore, although it is clear that plasma IL-6 is increased in cancer
cachexia, both in patients [28,39] and rodents [44], the source(s)
538 M.L. Batista Jr. et al. / Cytokine 61 (2013) 532–539of the cytokine has/have not been established. We thus propose
that SAT contributes in a relevant way to this parameter.
Up-regulation of IL-6 seems conspicuous in cachectic cancer
subjects [39,45], a result we also report. In advanced cancer pa-
tients, increased circulating levels of IL-6 are negatively related
to impairment of physical and cognitive functions [45] and associ-
ated with functional disability of daily living [46]. We additionally
show that up-regulation of IL-6 is also present in weight stable
cancer patients. Furthermore, the high IL-6 levels related with tu-
mour staging suggest that the primary tumour is an important
source of pro-cachectic cytokines in gastrointestinal cancer
patients.
In animal models of cachexia [14,44,47], the involvement of IL-
6, TNF-a, IL-1 and IL-10 seems to be well established, while clinical
studies on humans not always manage to conﬁrm the importance
of TNF-a and IL-6 [48]. Moreover, the participation of certain cyto-
kines in the pathomechanisms of weight loss in cancer-related ca-
chexia appears to depend on several factors, such as tumour type
[5], cancer TNM stage and experimental designing; individual con-
trols matched by age, sex, BMI. In this aspect, up-regulation of IL-6
has been a consistent ﬁnding in several studies, notably in cachec-
tic patients, independently of the etiology of the syndrome [28]. IL-
6 has relatively the longest half-life, which may explain why IL-6
but not TNF-a and IL-1, is frequently found to be augmented in
cancer, and associated with weight loss [28,49].
We suggest, based on the results of the present study, showing
plasma IL-6 to be robustly increased during the syndrome, that this
may represent an interesting tool for assessing cachexia. Despite
the fact that IL-10 plasma levels were not changed due to cachexia
and/or cancer, IL6/IL-10 ratio is a valuable tool for the determina-
tion of inﬂammatory and anti-inﬂammatory cytokine balance [50].
Increased IL-10 plasma concentration has been found to be associ-
ated with the process of chronic inﬂammation and worsened out-
come in several diseases [11]. Although this is not the case of the
cachectic cancer patients herein studied, at least considering IL-
10 changes, IL6/IL-10 ratio seems to be speciﬁcally increased by ca-
chexia and cancer association. Nevertheless, a more detailed study
on the adequacy of IL6/IL-10 ratio in the setting of cancer cachexia
is required.
Limitations of this study should be acknowledged. We have not
evaluated lean body mass among the groups, although they were
matched by BMI. In this aspect, the cohort of patient enrolled in
the current study may be not representative of a typical cancer
population from Europe or North America and some differences
such as; total fat mass from cancer groups and overweight and
obesity prevalence should be considered. Cachectic groups showed
values ranging from 11% to 25% of body weight loss in the previous
6 months and CRP higher than 5 lg/mL, indicating that we studied
patients staging between cachexia to refractory cachexia. Cancer
cachexia may have several etiologies, including malnutrition, anor-
exia and tumour-speciﬁc effects. Our study was performed with
patients with gastrointestinal adenocarcinoma, predominantly lo-
cated on colon and stomach, which are associated with signiﬁcant
weight loss. The current study was addressed to assess the effect of
cachexia and tumour per se but was not empowered to detect dif-
ferences between selective cancer forms. In this aspect, larger co-
horts with further grouping of patients according to tumour
phenotype could have resulted in other differences.5. Concluding remarks
In conclusion, our study shows systemic inﬂammation in
cachectic cancer patients, a characteristic that is important for both
the development of cancer and of cachexia. IL-6 plasma levels were
increased in both weight-stable and cachexia cancer patients, andthis change showed a positive relationship with IL-6 and cancer T
stage, suggesting an important role for this cytokine as a biomarker
of cancer cachexia. Plasma adiponectin was higher in patients with
cancer cachexia compared with cancer controls individually
matched by BMI. Furthermore, we also demonstrated a role for
the subcutaneous depot as a possible systemic source of such
molecules.
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